Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) target price increased to $16.00, reported today by FBR & Co
- Updated: September 15, 2016
Just yesterday Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded 0.92% higher at $7.70. The company’s 50-day average is $8.55 and its 200-day average is $8.38. The last stock price is down 8.16% relative to the 200-day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. 1,138,913 shares of ACHN exchanged hands, down from ann average trading volume of 1,296,830.
Indicating a possible upside of 1.08%, FBR & Co raised the price target of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $16
Recent Performance Graph:
A total of 5 equity analysts have released a research note on Achillion Pharmaceuticals, Inc.. Two analysts rate the stock a strong buy, one analyst rate the stock a buy, three firms rate the stock a hold, one firm rate the company to underperform, and lastly 0 brokeragesrate the company as sell with a consensus target stock price of $9.40
Achillion Pharmaceuticals, Inc. has a price-earnings of 157 with a 52 week low of $5.57 and a 52 week high of $10.95. Achillion Pharmaceuticals, Inc.’s market capitalization is presently $0.0.
More About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, and ACH-3422 and sovaprevir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.